International Scholarly Research Notices

Volume 2014 (2014), Article ID 278173, 5 pages

http://dx.doi.org/10.1155/2014/278173

Research Article

Development and Validation of Stability Indicating Spectroscopic Method for Content Analysis of Ceftriaxone Sodium in Pharmaceuticals

Revathi Ethiraj,¹ Ethiraj Thiruvengadam,² Venkattapuram Saravanan Sampath,¹ Abdul Vahid,¹ and Jithin Raj¹

¹Department of Pharmaceutical Analysis, The Erode College of Pharmacy, Erode, Tamil Nadu 638112, India

²Department of Pharmaceutics, The Erode College of Pharmacy, Erode, Tamil Nadu 638112, India

Received 10 March 2014; Accepted 14 May 2014; Published 24 August 2014

Academic Editor: Jose Vicente Garcia Mateo

Copyright © 2014 Revathi Ethiraj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

A simple, selective, and stability indicating spectroscopic method has been selected and validated for the assay of ceftriaxone sodium in the powder for injection dosage forms. Proposed method is based on the measurement of absorbance of ceftriaxone sodium in aqueous medium at 241 nm. The method obeys Beer’s law in the range of 5–50 μg/mL with correlation coefficient of 0.9983. Apparent molar absorptivity and Sandell’s sensitivity were found to be L mol⁻¹ cm⁻¹ and 0.02732 μg/cm²/0.001 absorbance units. This study indicated that ceftriaxone sodium was degraded in acid medium and also underwent oxidative degradation. Percent relative standard deviation associated with all the validation parameters was less than 2, showing compliance with acceptance criteria of Q2 (R1), International Conference on Harmonization (2005) guidelines. Then the proposed method was successfully applied to the determination of ceftriaxone sodium in sterile preparation and results were comparable with reported methods.

1. Introduction

Ceftriaxone sodium (Figure 1) is chemically (6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-ioxo-1,2,4-triazin-3-yl)thio]-methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid [1]. Ceftriaxone is a third generation, semisynthetic cephalosporin antibiotic. Cephalosporins are derivatives of 7-aminocephalosporic acid and are closely related to penicillins in structure. Ceftriaxone sodium is a long acting, broad-spectrum cephalosporin antibiotic for parenteral use. The bactericidal activity of ceftriaxone sodium results from inhibition of cell wall synthesis. It exerts in vitro activity against a wide range of Gram-negative and Gram-positive microorganisms. It is highly stable to most beta-lactamases, both penicillinases and cephalosporinases, of Gram-positive and Gram-negative bacteria.

Figure 1: Chemical structure of ceftriaxone sodium.

A thorough literature survey has revealed that HPLC method for ceftriaxone sodium with combination of other drugs and individually in dosage forms [2–15], microbial bioassay methods [16, 17], and spectrophotometric methods in dosage forms [18–22] have been reported for analysis of ceftriaxone sodium. Costlier and volatile solvents were used as mobile phase solvent system and the time of analysis was more in some reported methods.

Some spectrophotometric methods are recently described in the literature for analysis of drugs in raw material and finished products such as ceftazidime [23–25], cefuroxime [26], and cefazolin [27]. These spectrophotometric methods involve the use of no toxic organic solvents, which do not contribute to the generation of this kind of waste by the chemicals or industries. In this context, spectrophotometry stands out. Therefore, the trend is that the industries look for ways to reduce the impacts of their activities on the environment. So, the principle objective of this study was, therefore, to develop a simple, selective, precise, less time consuming, and economical method with a wide linear range and good sensitivity for assay of ceftriaxone sodium in the powder for injection dosage forms.

The parent drug stability guidelines issued by the international conference of harmonization (ICH) [28] require that analytical test procedure should indicate stability. Therefore, the present study was extended to establish the inherent stability of ceftriaxone sodium under different stress conditions such as, alkaline, acidic, oxidative, and photolytic conditions. Thus, this method can be utilized to compare the results for the content analysis of stability samples, since the purpose of stability studies is to monitor possible changes to a product or a material over a time at different storage conditions.

2. Materials and Methods

2.1. Instruments and Chemicals

Spectrophotometric analysis was carried out on a Systronics 2201, UV-visible double-beam spectrophotometer with matched 1 cm path-length quartz cells. Absorption spectra were recorded on a medium scan speed, setting slit width to be 1 nm. Ceftriaxone sodium was obtained as a gift sample from Orchid Chemicals and Pharmaceutical Ltd., Chennai, India. The other chemicals like sodium hydroxide, hydrochloric acid, and hydrogen peroxide used were of Merck-AR grade and double distilled water was used throughout the experiment.

2.2. Preparation of Standard Stock Solution

A stock solution was prepared by dissolving 100 mg of ceftriaxone sodium pure drug in 100 mL of distilled water to get standard stock solution (1 mg/mL).

2.3. Construction of the Calibration Curve

To a set of 10 mL volumetric flasks, aliquot volumes containing the drug were quantitatively transferred from standard stock solution and made up to the mark with distilled water to obtain final concentrations of 5–50 μg/mL of ceftriaxone sodium. The absorbance was measured at 241 nm and calibration graph was constructed by plotting the absorbance versus the concentration of the drug. Alternatively, the corresponding regression equation was derived.

2.4. Validation of the Proposed Method

The validity of the method was tested regarding linearity, specificity, accuracy, and precision according to ICH Q2B recommendations.

2.4.1. Accuracy and Precision

Accuracy and precision of the method were evaluated with the help of percent recovery, standard deviation (SD), and percent relative standard deviation (RSD) by using standard addition method. Three levels of standard drug (10%, 20%, and 30%) were spiked individually with the 100 mg equivalent of powder for injection dosage form ceftriaxone sodium and analysed in six replicates during the same day (intraday precision) and six consecutive days (interday precision). The results obtained were tabulated along with standard error and 95% confidence interval.

2.4.2. Linearity

A linear correlation was found between absorbance at λ max and various concentrations of ceftriaxone sodium. The linearity graph obeyed Beer’s law in the range from 5 to 50 μg/mL and it was described by regression equation () and correlation coefficient () which were displayed on the graph. Molar absorptivity, Sandell's sensitivity, standard error on slope, confidence limit of slope (95%), standard error on intercept, confidence limit of intercept (95%), LOD, and LOQ were calculated.

2.4.3. Limit of Detection (LOD) and Limit of Quantification (LOQ)

For the determination of LOD and LOQ, the method is based on residual standard deviation of regression line and slope. To determine LOD and LOQ, the specific calibration curve was studied using the sample containing analyte in the range of detection limit and quantitation limit.

2.4.4. Robustness

Robustness was studied by evaluating the influence of small but deliberate variations in the experimental condition like storing the similar concentration (20 μg/mL) of drug solution at two different temperatures (20°C and 30°C) for 1 h and performing the stability of the sample solution at various time intervals (after 1 h and after 6 h) on the analytical performance.

2.4.5. Forced Degradation Study

A 2 mL aliquot of standard stock solution of ceftriaxone sodium (1 mg/mL) was taken in four replicates in a volumetric flask (100 mL) and mixed with 10 mL of 0.1 N HCl (acid hydrolysis) or 0.1 N NaOH (alkaline hydrolysis) or 5% H₂O₂ (oxidative degradation) and set aside for 1 h at room temperature. Solution was diluted up to mark with distilled water. For photolytic degradation, a solution of drug (20 μg/mL) was prepared as per the procedure under construction of the calibration graph and was exposed to UV radiation of wavelength 254 nm and of 1.4 flux intensity for 24 h in a UV chamber. For thermal degradation solid drug was kept in an oven at 100°C for 24 h. After cooling to room temperature, 20 μg/mL concentrated drug solution was prepared as per above said method. Finally, absorbance of all the solutions resulted from acid and alkaline hydrolysis, and oxidative degradation, photolytic degradation, and thermal degradation were measured at 241 nm against respective solvent as blank in each case.

2.5. Application of Developed Method to Analyse Drug Formulation

For the estimation ceftriaxone sodium from injection (by procuring three brands from market), a portion of powder equivalent to 100 μg of the drug from each brand was accurately weighed and transferred into 100 mL volumetric flask. The drug was dissolved by adding 70 mL of distilled water and sonicated for 15 min. The volume was completed with distilled water and filtered. Aliquot containing suitable concentration (20 μg/mL) of ceftriaxone sodium was analyzed as described under construction of the calibration graph. The nominal content of the drug in injection for each brand was determined using the corresponding regression equation and results of %RSD of drug content were statistically compared with reported method.

3. Results and Discussion

Aqueous solution of ceftriaxone sodium showed absorbance maximum (λ max) at 241 nm (Figure 2), and at this wavelength distilled water did not show any significant absorbance. Therefore further analysis was carried out at 241 nm.

Figure 2: Overlay spectrum for ceftriaxone sodium (λ max at 241 nm).

Least square regression equation of ceftriaxone sodium in aqueous medium has shown that the value very close to 1 indicated high degree of correlation between two variables, such as absorbance and concentration (Figure 3). Beer’s law was obeyed over the range of 5–50 μg/mL; high values of molar absorptivity and low values of Sandell's sensitivity and LOD revealed that proposed methods are highly sensitive. LOD and LOQ values for the drug were found and all the parameters of calibraration curve were displayed in Table 1.

Table 1: Linearity data of developed method.

Parameters
Values

max (nm)
241

Linearity range (g/mL)
5–50

LOD (g/mL)
0.0332

LOQ (g/mL)
0.1008

Molar absorptivity (L mol⁻¹cm⁻¹)
2.046 × 10³

Sandell’s sensitivity (g/cm²/0.001 absorbance unit)
0.02732

Slope
0.03576

Standard error on slope
0.0007346

Confidence limit of slope (95%)
0.03387–0.03765

Intercept
0.01246

Standard error on intercept
0.02064

Confidence limit of intercept (95%)
0.04060–0.06551

Correlation coefficient
0.9979

Standard deviation of residuals
0.03360

Figure 3: Calibration curve for ceftriaxone sodium.

To check accuracy and precision, assays were carried out for six times within a day (intraday precision) and in six consecutive days (interday precision) by adding three different levels of analyte to the formulation. % RSD values were ≤0.5 (intraday) and ≤1.18 (interday) indicating high precision of developed method. Accuracy of the method was ascertained as mean % recovery between measured actual concentration and taken concentration for ceftriaxone sodium. The values of % recovery, very close to 100%, demonstrate high accuracy of the proposed method (Table 2).

Table 2: Interday and intraday accuracy and precision study data.

Level of standard drug added
Interday
Intraday

Mean % recovery*
% RSD*
S.E
95% CI
Mean % recovery*
% RSD*
S.E
95% CI

10%
101.10
0.69
0.4041
99.36–102.84
100.27
0.50
0.2906
99.01–101.52

20%
100.97
1.18
0.6984
99.60–101.90
99.23
0.20
0.1202
98.71–99.75

30%
100.43
1.10
0.6386
97.68–103.18
100.6
0.39
0.2309
99.60–101.59

; % RSD: percentage relative standard deviation; S.E: standard error; 95% CI: 95 percent confidence interval.

Robustness studies assumed that the small variations in any of the variables did not significantly affect the results (Table 3). This provided an indication for the reliability of the proposed method during routine analysis.

Table 3: Data for robustness of the method.

Parameters
Mean % content
% RSD

Temperature

    at 20°C
99.72
1.1055

    at 30°C
100.49
1.7369

Time

    after 1 hr
101.74
1.0835

    after 6 hr
100.23
1.7414

Ceftriaxone sodium sterile formulations were analysed by proposed method and by reported method [21], which involved the analysis of analyte with 0.1 M sodium hydroxide and absorbance measured at 258.8 nm. Results were compared by Student’s t-test and variance-ratio -test. Calculated -values and -values did not exceed tabulated values of 2.776 () and 6.39 () at 95% confidence level and for four degrees of freedom (Table 4) which indicates close similarity between proposed and reported method.

Table 4: Statistical comparison of proposed method with reference method.

Brand name
% RSD for % content*
Statistical data

Proposed method
Reference method
Variance-ratio -test
Student’s -test

Cefaxone
0.893
0.672
1.748
0.8819

Cadiceft
0.435
0.555
1.574
2.215

Monocef
1.057
0.468
5.098
0.1255

().

Stability indicating property of analyte was performed by forced degradation studies. Ceftriaxone sodium was subjected to various stress conditions like acid, alkaline, hydrogen peroxide induced degradation, and thermal and photolytic condition. Analysis was performed by measuring absorbance of ceftriaxone sodium after subjecting it to stressed conditions at λ max of pure drug. Percentage degradation was calculated by the formula: % degradation = (expected concentration−actual concentration)/expected concentration × 100, and percentage recovery also was calculated for each case (Table 5). Results revealed no change in absorbance of drug solution at alkaline hydrolysis, so its percentage recovery is very close to 100% which indicates the drug stability. The analyte showed slight degradation with UV and thermal stressed condition. But there was significant change in absorbance after acid and hydrogen peroxide treatment, confirming that ceftriaxone sodium is susceptible to acid hydrolysis (% degradation of 11.0%) and oxidation (% degradation of 7.95%).

Table 5: Results for stability of drug under forced degradation study.

Parameters studied
Conc. taken (g/mL)
Conc. found (g/mL)
% degradation
% recovery

Acid hydrolysis
20
7.80
11.0
89.0%

Alkaline hydrolysis
20
20.07
−0.35
100.35%

Oxidative degradation
20
18.41
7.95
92.05%

UV degradation
20
21.69
−8.45
108.45%

Thermal degradation
20
19.31
3.45
96.55%

4. Conclusion

Ceftriaxone sodium was subjected to various studies as per ICH guidelines. Analyte undergoes significant degradation under acid hydrolysis and oxidation, whereas it is stable under alkaline treatment. Proposed method was validated for linearity, accuracy, precision, and robustness and method was applied to various formulations and results were statistically compared with reference method which showed that there were no significant changes in the result. So, method can be utilized for determination of purity of drug available from various sources without any tedious procedure and also used in analysis of stability study samples.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The authors are grateful to the Erode College of Pharmacy, Tamil Nadu, India, for giving permission to carry out their research work.

References

S. Budavari, The Merck Index, Merck & Corporation, White House Station, NJ, USA, 13th edition, 2001.

A. Tariq, M. R. Siddiqui, J. Kumar et al., “Development and validation of high performance liquid chromatographic method for the simultaneous determination of ceftriaxone and vancomycin in pharmaceutical formulations and biological samples,” Science Asia, vol. 36, no. 4, pp. 297–304, 2010.

J. Shah, M. R. Jan, S. Shah, and M. N. Khan, “Development and validation of HPLC method for simultaneous determination of ceftriaxone and cefaclor in commercial formulations and biological samples,” Journal of the Mexican Chemical Society, vol. 57, no. 4, pp. 314–320, 2013.

H. Sun, H. Wang, X. GE, and X. Quin, “Simultaneous determination of the combined drugs ribavarin and ceftriaxone sodium in human urine by HPLC-DAD,” International Journal of Science Innovations and Discoveries, vol. 1, no. 2, pp. 216–225, 2011.

R. S. Kale, H. K. Jain, P. D. Ghode et al., “An rphplc method for simultaneous estimation of Ceftriaxone sodium and sulbactam sodium in parenteral dosage form,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, supplement 5, pp. 406–409, 2011.

R. N. Kumar, G. N. Rao, and P. Y. Naidu, “Stability indicating fast LC method for determination of ceftriaxone and tazobactam for injection related substances in bulk and pharmaceutical formulation,” International Journal of Applied Biology and Pharmaceutical Technilogy, vol. 1, no. 1, pp. 145–157, 2010.

S. M. Shrivastava, R. Singh, A. Tariq et al., “A novel high performance liquid chromatographic method for simultaneous determination of ceftriaxone and sulbactam in sulbactomax,” International Journal of Biomedical Science, vol. 5, no. 1, pp. 37–43, 2009.

B. P. Nirav, C. A. Alpesh, K. J. Sneha, D. M. Vipul, and T. D. Hemant, “Development and validation of stability indicating method for simultaneous estimation of ceftriaxone and sulbactam injection using RP-UPLC method,” IOSR Journal of Pharmacy, vol. 2, no. 6, pp. 29–37, 2012.

M. Gandhimathi, M. S. Kumar, and T. K. Ravi, “Validated ion pair HPLC method for simultaneous estimation of ceftriaxone sodium and tazobactum sodium in dosage form,” International Journal of Pharma and Bio Sciences, vol. 1, no. 4, pp. 17–22, 2010.

B. Shrestha, N. R. Bhuyan, and B. N. Sinha, “Development and validation of a stability indicating HPLC method for estimation of ceftriaxone and sulbactam in sterile powder for injection,” International Journal of PharmTech Research, vol. 4, no. 4, pp. 1660–1666, 2012.

N. Sultana, M. S. Arayne, and W. Shahzad, “Simultaneous determination of ceftriaxone sodium and statin drugs in pharmaceutical formulations and human serum by RP-HPLC,” Journal of the Chilean Chemical Society, vol. 55, no. 2, pp. 193–198, 2010.

B. Hiremath and B. H. M. Mruthyunjayaswamy, “Development and validation of a high-performance liquid chromatographic determination of ceftriaxone sodium and its application to drug quality control,” Analytical Letters, vol. 42, no. 14, pp. 2180–2191, 2009.

K. S. Rao, B. Rao, S. Patro, and A. Patnaik, “Development and validation of new analytical method for ceftriaxone sodiumin bulk and pharmaceutical dosage forms,” International Journal of Research and Reviews in Pharmacy and Applied Science, vol. 2, no. 3, pp. 556–565, 2012.

M. de Diego, G. Godoy, and S. Mennickent, “Chemical stability of ceftriaxone by a validated stability-indicating liquid chromatographic method,” Journal of the Chilean Chemical Society, vol. 55, no. 3, pp. 335–337, 2010.

N. Pal, A. S. Rao, and M. A. Hedi, “HPLC method development and validation for the assay of ceftriaxone sodium injection,” International Journal of Pharma Sciences, vol. 2, no. 4, pp. 84–90, 2012.

N. A. Dafale, U. P. Semwal, P. K. Agarwal, P. Sharma, and G. N. Singh, “Quantification of ceftriaxone sodium in pharmaceutical preparations by a new validated microbiological bioassay,” Analytical Methods, vol. 4, no. 8, pp. 2490–2498, 2012.

P. V. Aléssio and H. R. N. Salgado, “Development and validation of a successful microbiological agar assay for determination of ceftriaxone sodium in powder for injectable solution,” Pharmaceutics, vol. 4, no. 3, pp. 334–342, 2012.

K. R. Patel, V. D. Patel, K. P. Patel, and V. G. Patel, “Development and validation of spectrophotometric method for determination of ceftriaxone sodium in pharmaceutical dosage forms,” Der Pharma Chemica, vol. 2, no. 5, pp. 255–260, 2010.

S. Sharma and M. C. Sharma, “Simultaneous estimation and validation of ceftriaxone sodium and tazobactum sodium from pharmaceutical dosage forms using indigocarmine, methyl orange dye,” World Journal of Chemistry, vol. 6, no. 1, pp. 53–58, 2011.

I. F. Al-Momani, “Spectrophotometric determination of selected cephalosporins in drug formulations using flow injection analysis,” Journal of Pharmaceutical and Biomedical Analysis, vol. 25, no. 5-6, pp. 751–757, 2001.

K. S. Lakshmi, K. Ilango, N. Nithya mathi, S. Balaji, D. W. Kibevictor, and V. Sathish Kumar, “Spectrophotometric methods for the estimation of cefriaxone sodium in vials,” International Journal of Pharmaceutical Science, vol. 1, no. 1, pp. 22–25, 2009.

C. M. B. Reddy and G. V. Subbareddy, “Development and validation of UV-spectrophotometric methods for estimation of ceftriaxone in bulk and tablet dosage form,” International Journal of ChemTech Research, vol. 5, no. 1, pp. 472–477, 2013.

A. D. H. Moreno and H. R. N. Salgado, “Spectrophotometric determination of ceftazidime in pharmaceutical preparations using neocuproin as a complexing agent,” Analytical Letters, vol. 41, no. 12, pp. 2143–2152, 2008.

A. H. Moreno and H. R. N. Salgado, “Rapid and selective UV spectrophotometric method for the analysis of ceftazidime,” Journal of AOAC International, vol. 92, no. 3, pp. 820–823, 2009.

A. H. Moreno and H. R. N. Salgado, “Stability study and degradation kinetics of ceftazidime in pharmaceutical preparations,” Advances in Analytical Chemistry, vol. 2, no. 1, pp. 1–5, 2012.

D. C. M. Vieira and H. R. N. Salgado, “Comparison of HPLC and UV spectrophotometric methods for the determination of cefuroxime sodium in pharmaceutical products,” Journal of Chromatographic Science, vol. 49, no. 7, pp. 508–511, 2011.

T. M. Pedroso and H. R. N. Salgado, “Validation of cefazolin sodium in pharmaceutical dosage forms by UV-spectrophotometric method,” Physical Chemistry, vol. 3, pp. 11–20, 2013.

“ICH guidelines on validation of analytical procedures: text and methodology Q2 (R1),” in Proceedings of the International Conference on Harmonisation, pp. 1–8, Geneva, Switzerland, 2005.